SavedAdd your journal

Journals / Turkish Journal of Hematology / 2013 / Cilt: 30 - Sayı: 3

Multiple myelomada yaşam kalitesi ve destek tedavisi

Quality of life and supportive care in multiple myeloma

Melda CÖMERT
Ajda GÜNEŞ ERSOY
FAHRİ ŞAHİN
Güray SAYDAM
Pages
234–246
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this review is to highlight the relationship among life of quality, supportive care, and improvement in survival.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Multiple myeloma is the second most common haematological malignancy.
📊
Key Findings & Data:Novel therapies have led to improvement in survival.
💡
Conclusion & Impact:The aim of this review is to highlight the relationship among life of quality, supportive care, and improvement in survival.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Multiple myeloma is the second most common haematological malignancy. Novel therapies have led to improvement in survival. Current myeloma management is matching the progress made in improved survival through disease control while optimising quality of life with effective supportive care. Supportive treatment is an essential part of the therapeutic management of myeloma patients because it is directed towards improving the patient s quality of life and also can improve survival. The aim of this review is to highlight the relationship among life of quality, supportive care, and improvement in survival.

Özet

Multipl miyelom en sık görülen ikinci hematolojik malignitedir. Yeni tedaviler sağkalımda iyileşme sağlamıştır. Günümüzde uygulanan miyelom tedavi yönetimi, hastalığı kontrol altına alarak sağkalımda iyileşme sağlarken etkili destekleyici tedavi ile de yaşam kalitesini artırmaktadır. Destekleyici tedavi, hastaların yaşam kalitesini artırması ve sağkalımı iyileştirmesi nedeni ile miyelom hastalarının tedavi yönetiminin önemli bir parçasıdır. Bu derlemenin amacı yaşam kalitesi, destekleyici tedavi ve sağkalımdaki iyileşme arasındaki ilişkiyi vurgulamaktır.

🔖

Cite This Article

CÖMERT, M., ERSOY, A. G., ŞAHİN, F., SAYDAM, G. (2013). Multiple myelomada yaşam kalitesi ve destek tedavisi. Turkish Journal of Hematology, Cilt: 30 - Sayı: 3, 234–246. https://ajindex.com/articles/412853

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011
  2. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008
  3. Brenner H, Gondos A, Pulte D. Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica 2009
  4. Wagner LI, Robinson D Jr, Weiss M, Katz M, Greipp P, Fonseca R, Cella D. Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction. J Pain Symptom Manage 2012
  5. Etto LY, Morelli VM, Silva VC, Hungria VT, Ciconelli RM, Almeida MS, Oliveira JS, Barros JC, Durie BG, Colleoni GW. Autologous stem cell transplantation improves quality of life in economically challenged, Brazilian multiple myeloma patients. Clinics 2011
  6. Snowden JA, Ahmedzai SH, Ashcroft J, D’Sa S, Littlewood T, Low E, Lucraft H, Maclean R, Feyler S, Pratt G, Bird JM
  7. Haemato-oncology Task Force of British Committee for Standards in Haematology and UK Myeloma Forum. Guidelines for supportive care in multiple myeloma 2011. Br J Haematol 2011
  8. Bergner M. Quality of life, health status, and clinical research. Med Care 1989
  9. 27(Suppl 3):148-156. 8.Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, editor. Evaluation of Chemotherapeutic Agents. New York, Columbia University Press, 1949. 9.Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984
  10. Cella D, Wagner L, Cashy J, Hensing TA, Yount S. Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment of cancer therapy. J Natl Cancer Inst Monogr 2007
  11. Wisløff F Hjorth M. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol 1997
  12. Sloan JA, Cella D, Frost M, Guyatt GH, Sprangers M, Symonds T
  13. Clinical Significance Consensus Meeting Group. Assessing clinical significance in measuring oncology patient quality of life: introduction to the symposium, content overview, and definition of